For decades, most doctors, me included, focused on the usual suspects when assessing heart disease risk: LDL cholesterol, HDL cholesterol, triglycerides, blood pressure, and lifestyle factors like smoking, activity, and diet. But lurking in the background was another player that most of us didn’t routinely check and most patients had never heard of—lipoprotein(a), abbreviated as Lp(a) and pronounced “L-P-little-A.”

Here’s the sobering reality: about one in five people worldwide have elevated Lp(a) levels, and if you’re among them, your risk of heart attack or stroke roughly doubles or triples. Yet until recently, most clinical guidelines didn’t even recommend testing for it. Why? Because there wasn’t much doctors could do about it even if we found it. That’s changing now, and the story of Lp(a) offers a window into how medicine sometimes waits for treatment options before fully embracing a diagnostic test.

What Exactly Is Lipoprotein(a)?

Lp(a) is structurally similar to LDL cholesterol—both are cholesterol-carrying particles—but Lp(a) has an extra protein component called apolipoprotein(a), or apo(a), that makes it particularly troublesome. The structure of this protein varies dramatically between individuals due to differences in genetic sequences, and the specific variant you inherit from your parents determines your Lp(a) level for life.

Unlike LDL cholesterol, which rises with age and responds to diet and exercise, your Lp(a) level remains largely constant throughout your lifetime. Eating better, exercising more, losing weight—none of the lifestyle interventions that work wonders for other cardiovascular risk factors will budge your Lp(a). It’s entirely genetic. There’s also significant variation across populations, with individuals of African descent tending to have higher average Lp(a) levels compared to people of White or Asian backgrounds, though the clinical implications of these differences are still not well understood.

Getting Tested: Who Should Do It and How Does It Works

The blood test for Lp(a) isn’t part of a routine cholesterol panel—your doctor has to specifically order it. So, who should be tested? Current recommendations focus on people with a family history of high Lp(a), those with a personal or family history of premature heart disease (cardiovascular events before age 55 in men or 65 in women), and anyone diagnosed with familial hypercholesterolemia, a genetic condition where the body poorly recycles LDL cholesterol. About a third of people with familial hypercholesterolemia also have high Lp(a), compounding their cardiovascular risk significantly.

Because Lp(a) levels don’t change over time, a single test is all you need. Results can be reported in two different units—milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L)—and there’s no universal agreement on what constitutes a risky level. Most American guidelines use a threshold of ≥50 mg/dL or ≥125 nmol/L as indicating increased cardiovascular risk, with levels below 30 mg/dL generally considered normal.

What High Lp(a) Means for Your Health

The evidence linking elevated Lp(a) to cardiovascular disease has become increasingly compelling over the past two decades. People with high Lp(a) face a two to threefold increased risk of heart attack and aortic valve disease. For those with extremely elevated levels above 180 mg/dL, the cardiovascular risk approaches that of people with untreated familial hypercholesterolemia (genetic extremely high cholesterol), which is notoriously dangerous.

Beyond heart attacks and valve problems, elevated Lp(a) has been linked to peripheral arterial disease (clogged arteries) and aortic aneurysms. What makes it particularly insidious is that it contributes to what researchers call “residual cardiovascular risk”—meaning it raises your chances of a cardiovascular event even when your LDL cholesterol is well controlled. You could be doing everything right by traditional measures and still be at elevated risk if your Lp(a) is high.

A large multi-ethnic study following nearly 28,000 people for an average of 21 years found that higher Lp(a) levels were consistently associated with greater cardiovascular disease risk across different ethnic groups and in both men and women. The mechanism involves both promoting arterial plaque buildup and increasing blood clot formation—a double threat to cardiovascular health.

Current Management Options: Limited but Important

This is where the story gets frustrating. For years, the honest answer to “what can I do about my high Lp(a)?” has been: not much directly, but a few things indirectly.

While lifestyle changes won’t affect your Lp(a) numbers, people with high levels should still follow all standard heart-healthy practices—physical activity, good nutrition, adequate sleep, avoiding smoking, and maintaining a healthy weight. The logic is straightforward: if you can’t eliminate one major risk factor, be more diligent about controlling all the others.

People with high Lp(a) may also benefit from more aggressive LDL cholesterol treatment, even if their LDL is already in a normal range. Some injectable cholesterol medications can lower Lp(a) by about 20% in some patients in addition to their primary effect on LDL. This helps overall cardiovascular risk even if it doesn’t fully address the Lp(a) problem.

For the most severe cases, the only FDA-approved treatment specifically targeting Lp(a) lipoprotein is apheresis which filters apolipoprotein-containing particles from the blood, achieving over 50% reduction. But the reductions are temporary, the procedure is similar to dialysis in its time demands, and it’s expensive and reserved for only the most extreme situations. It’s not a practical solution for the millions of people with moderately elevated levels.

The Treatment Revolution: New Therapies on the Horizon

Here’s where things get genuinely exciting. After decades of essentially no targeted treatment, five promising new therapies are now in advanced clinical development.

Four are RNA-based therapies that work by silencing the gene responsible for producing apolipoprotein(a) in the liver thereby preventing Lp(a) formation at its source. All are engineered to be taken up specifically by liver cells, where Lp(a) is made to minimize side effects elsewhere.

Early trial results have been remarkable. One drug, given as a monthly injection under the skin, has reduced Lp(a) levels by about 80%, with 98% of participants achieving levels below the risk threshold of 50 mg/dL. A phase 3 trial enrolling over 8,300 patients is expected to report results sometime in 2026, potentially leading to regulatory approval shortly after.

Other drugs have shown even more dramatic results, with one achieving a 93.9% reduction in Lp(a) with a single dose, with the effect persisting above 90% even at 360 days after just one injection.

There’s also an oral medication in development which works by preventing the apo(a) protein from assembling into Lp(a) particles in the first place. Taken daily as a pill, it has shown reductions of 63-65%—less dramatic than the RNA-based therapies, but potentially preferable for patients who want to avoid injections entirely.

The Critical Caveat

While these medications dramatically lower Lp(a) levels, we don’t yet have definitive proof that lowering Lp(a) will prevent heart attacks and strokes. That sounds counterintuitive—if high Lp(a) causes cardiovascular disease, then lowering it should help—but medicine requires rigorous evidence from randomized controlled trials. The FDA won’t approve these drugs based solely on their ability to improve a lab value; they need to demonstrate actual clinical benefit. Large outcome trials are underway and we should have answers within the next few years.

Where Things Stand Now

The story of Lp(a) reflects a broader tension in medicine: when should we test for something we can’t yet treat? For decades, many argued against routine screening precisely because no targeted therapies existed. That calculus has shifted. Recent reviews have concluded that the benefits of early detection now outweigh the risks, even though specific Lp(a)-lowering drugs are not yet approved, because early knowledge allows for more aggressive management of other risk factors.

For the roughly 20-25% of people with elevated Lp(a), the next few years could bring transformative options. If you fall into one of the higher-risk groups and have never been tested, it’s worth asking your doctor whether screening makes sense. The treatment landscape for Lp(a) is changing faster than it has in decades, and knowing your number today puts you in a much better position to act when those new options arrive.

Illustration generated by the author using ChatGPT.

Sources

American Heart Association. (n.d.). Lipoprotein (a). https://www.heart.org/en/health-topics/cholesterol/genetic-conditions/lipoprotein-a

American Heart Association. (n.d.). Lipoprotein (a) meaning and how does it impact my heart health? https://www.heart.org/en/health-topics/cholesterol/genetic-conditions/lipoprotein-a-risks

Beck, D. L. (2025). Lipoprotein(a): An independent risk factor for CV disease. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/feature-lipoprotein-a

Centers for Disease Control and Prevention. (2025). About lipoprotein (a). https://www.cdc.gov/heart-disease-family-history/about/about-lipoprotein-a.html

Cleveland Clinic. (2025). Novel siRNA reduces lipoprotein(a) by more than 90% for 48 weeks. https://consultqd.clevelandclinic.org/novel-sirna-reduces-lipoproteina-by-more-than-90-for-48-weeks

Corliss, J. (2025). Lipoprotein(a): An update on testing and treatment. Harvard Health Publishing. https://www.health.harvard.edu/heart-health/lipoproteina-an-update-on-testing-and-treatment

Grundy, S. M., & Stone, N. J. (2022). Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(1), e48-e60. https://www.ahajournals.org/doi/10.1161/ATV.0000000000000147

Katsiki, N., et al. (2023). An update on lipoprotein(a): The latest on testing, treatment, and guideline recommendations. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Articles/2023/09/19/10/54/An-Update-on-Lipoprotein-a

Lombardi, A., et al. (2024). Lipoprotein (a): Underrecognized risk with a promising future. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11607505/

Lombardo, C., et al. (2025). Lp(a)-lowering agents in development: A new era in tackling the burden of cardiovascular risk? PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12115060/

Managed Healthcare Executive. (2025). New therapies on the way to lower Lp(a), a cardiovascular risk factor. https://www.managedhealthcareexecutive.com/view/new-therapies-on-the-way-to-lower-lp-a-a-cardiovascular-risk-factor

Papathanasiou, M., et al. (2025). Current clinical trials for treating elevated lipoprotein(a). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12282488/

Sabatine, M. S., et al. (2025). Lipoprotein(a) as a pharmacological target: Premises, promises, and prospects. Circulation. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069210

StatPearls. (2024). Lipoprotein A. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK570621/

Tsimikas, S., et al. (2025). Pelacarsen: Mechanism of action and Lp(a)-lowering effect. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S1933287425003228

Tsimikas, S., et al. (2025). Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2666667725000182

Wong, N. D., et al. (2024). Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. Journal of the American College of Cardiology. https://www.jacc.org/doi/10.1016/j.jacc.2024.02.031

Zambon, A., et al. (2023). Lipoprotein(a) as a risk factor for cardiovascular diseases: Pathophysiology and treatment perspectives. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10531345/